Aparna Parikh, MD

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    C2i genomics
    Topic: 
    Advisor/consultant
    Date added: 
    11/16/2021
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Pfizer
    Topic: 
    Advisor/consultant
    Date added: 
    11/16/2021
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Roche
    Topic: 
    Advisor/consultant
    Date added: 
    11/16/2021
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Eli Lilly
    Topic: 
    Advisor/consultant
    Date added: 
    11/16/2021
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Inivata
    Topic: 
    Advisor/consultant
    Date added: 
    04/14/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Biofidelity
    Topic: 
    Advisor/consultant
    Date added: 
    04/14/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Natera
    Topic: 
    Advisor/consultant
    Date added: 
    04/14/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Checkmate Pharmaceuticals
    Topic: 
    Advisor/consultant
    Date added: 
    04/14/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    FMI
    Topic: 
    Advisor/consultant
    Date added: 
    04/14/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Other
    Ineligible company: 
    Guardant
    Topic: 
    Advisor/consultant
    Date added: 
    04/14/2022

Pages

Return to 2023 Summit on Cancer Health Disparities: Reframing and Addressing Barriers to Adoption of Precision Oncology